English (UK)
中文版Mr. Jasper Wu
2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.
Zhaoyou Investment
Head of ResearchJeffrey Wu
Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies to patients with cancer, autoimmune and infectious diseases in China and around the world.
Convalife
VP - Strategic Partnering & Business DevelopmentDandan Xie
Focused in genitourinary（GU）/women health field with 2 global assets for bladder cancer and pre-cervical cancer treatment in phase 3 stages，looking for in/out-licensing partnership in GU/women health area
Asieris Pharmaceuticals
BD DirectorGrace Xie
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Responsive Web Design powered by 